Premium
T Cell Subsets Predicting Belatacept‐Resistant Rejection: Finding the Root Where the Trouble Starts
Author(s) -
Wekerle T.
Publication year - 2017
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.14390
Subject(s) - belatacept , medicine , immunosuppression , blockade , cd28 , immunology , cd80 , abatacept , t cell , immune system , cd86 , calcineurin , transplantation , antibody , cytotoxic t cell , receptor , biology , kidney transplantation , kidney transplant , rituximab , biochemistry , cd40 , in vitro
A nonhuman primate study from Mathews et al ( page 2285) and a clinical study from Cortes‐Cerisuelo et al ( page 2350) identify pretransplant T cell subsets predicting the risk of rejection with belatacept therapy, defining biomarkers that may eventually allow personalization of immunosuppression based on pretransplant immune status and thus lead to increased biomarker‐driven belatacept use.